Carcinoma, Hepatocellular

Oncology
35
Pipeline Programs
17
Companies
50
Clinical Trials
3 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
5
10
0
7
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1878%
Monoclonal Antibody
522%
+ 14 programs with unclassified modality

On Market (4)

Approved therapies currently available

Sanofi
ELOXATINApproved
oxaliplatin
Sanofi
Platinum-based Drug [EPC]intravenous2005
E
LENVIMAApproved
lenvatinib
Eisai
Kinase Inhibitor [EPC]oral2015
Bayer
STIVARGAApproved
regorafenib
Bayer
oral2013
Roche
TECENTRIQApproved
atezolizumab
Roche
injection2016

Competitive Landscape

17 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
8 programs
1
1
2
1
LenvatinibPhase 4Small Molecule1 trial
LenvatinibPhase 3Small Molecule1 trial
lenvatinibPhase 3Small Molecule1 trial
LenvatinibPhase 2Small Molecule1 trial
LenvatinibPhase 1Small Molecule1 trial
+3 more programs
Active Trials
NCT04008082Completed412Est. Jan 2022
NCT03663114Completed713Est. Feb 2020
NCT04763408Completed335Est. Dec 2023
+5 more trials
Bayer
BayerLEVERKUSEN, Germany
6 programs
1
2
1
1
RegorafenibPhase 3Small Molecule1 trial
BAY73-4506Phase 21 trial
RefametinibPhase 2Small Molecule3 trials
STIVARGA(Regorafenib)Phase 1Small Molecule5 trials
Gd-EOB-DTPAN/A1 trial
+1 more programs
Active Trials
NCT01490203Completed71Est. Dec 2016
NCT01012011Completed2,845Est. Aug 2015
NCT01689376No Longer Available
+9 more trials
Roche
RocheSTAVANGER NORWAY, Norway
4 programs
2
1
1
1
AtezolizumabPhase 3Monoclonal Antibody1 trial
AtezolizumabPhase 1/2Monoclonal Antibody1 trial
OnartuzumabPhase 1Monoclonal Antibody1 trial
RO5323441Phase 11 trial
Active Trials
NCT01897038Completed9Est. Mar 2015
NCT01308723Completed6Est. Jan 2012
NCT05908786Completed62Est. Nov 2025
+1 more trials
Sanofi
SanofiPARIS, France
2 programs
1
1
1
ELOXATIN(Oxaliplatin)Phase 25 trials
DENSPM )Phase 1/21 trial
Active Trials
NCT00081900Terminated38Est. Nov 2007
NCT00238849Unknown40
NCT03279289Completed170Est. Feb 2023
+3 more trials
Bristol Myers Squibb
2 programs
1
1
BrivanibPhase 3Small Molecule1 trial
BrivanibPhase 1Small Molecule5 trials
Active Trials
NCT01540461Completed17Est. Nov 2013
NCT01367275Terminated8Est. Nov 2013
NCT01046864Completed49Est. Jun 2014
+3 more trials
Accuray
AccurayMADISON, WI
1 program
1
CyberKnifePhase 31 trial
Active Trials
NCT01327521Withdrawn0
Novartis
NovartisBASEL, Switzerland
1 program
1
SomatostatinPhase 3Small Molecule1 trial
Active Trials
NCT00386984Completed108Est. Feb 2003
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
3 programs
1
2
SorafenibPhase 2Small Molecule1 trial
SorafenibPhase 2Small Molecule1 trial
Nintedanib high dosePhase 11 trial
Active Trials
NCT01594125Completed30Est. Jan 2015
NCT01004003Completed125Est. Oct 2016
NCT00987935Completed134Est. Jan 2016
Guerbet
GuerbetFrance - Villepinte
1 program
1
Idarubicin and LipiodolPhase 21 trial
Active Trials
NCT03727633Recruiting53Est. Jun 2026
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
Immuncell-LCPhase 21 trial
Active Trials
NCT02856815CompletedEst. Sep 2022
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY2157299Phase 21 trial
Active Trials
NCT01246986Completed204Est. Dec 2019
BioGene Therapeutics
1 program
1
TislelizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05366829RecruitingEst. Jun 2027
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
Tepotinib 300 mgPhase 1/21 trial
RegorafenibPhase 1Small Molecule1 trial
Active Trials
NCT03347292Completed58Est. Sep 2022
NCT01988493Completed117Est. Dec 2020
GSK
GSKLONDON, United Kingdom
1 program
1
MapatumumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT01258608Completed101Est. Nov 2017
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-08634404Phase 1/21 trial
Active Trials
NCT07227012Recruiting138Est. Oct 2028
CT
1 program
1
IGRTPhase 1
HistoSonics
HistoSonicsMI - Ann Arbor
1 program
VORTX Rx treatmentN/A1 trial
Active Trials
NCT03741088Completed8Est. Jul 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
EisaiLenvatinib
BayerRegorafenib
BayerRegorafenib
SanofiOxaliplatin
SanofiOxaliplatin
BayerRegorafenib
BayerRegorafenib
RocheAtezolizumab
EisaiLenvatinib
Eisailenvatinib
BayerRegorafenib
BayerRegorafenib
SanofiOxaliplatin
SanofiOxaliplatin
BayerRegorafenib

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 13,589 patients across 50 trials

NCT04297254EisaiLenvatinib

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Start: Feb 2021Est. completion: Jul 202350 patients
Phase 4Completed
NCT03564938BayerRegorafenib

Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Start: Jul 2018Est. completion: Dec 2023100 patients
Phase 4Completed
NCT02287025BayerRegorafenib

A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?

Start: Nov 2014Est. completion: Apr 201623 patients
Phase 4Terminated
NCT00129870SanofiOxaliplatin

CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer

Start: Feb 2005Est. completion: Dec 2007180 patients
Phase 4Terminated
NCT00263055SanofiOxaliplatin

MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV

Start: Aug 2004
Phase 4Completed
NCT04777851BayerRegorafenib

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Start: Oct 2023Est. completion: Feb 202645 patients
Phase 3Terminated
NCT04879368BayerRegorafenib

RegoNivo vs Standard of Care Chemotherapy in AGOC

Start: Jun 2021Est. completion: Jun 2026450 patients
Phase 3Active Not Recruiting
NCT04487067RocheAtezolizumab

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Start: Aug 2020Est. completion: Aug 2024152 patients
Phase 3Completed
NCT04246177EisaiLenvatinib

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Start: May 2020Est. completion: Mar 2026480 patients
Phase 3Active Not Recruiting
NCT03713593Eisailenvatinib

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Start: Dec 2018Est. completion: Sep 2024794 patients
Phase 3Completed
NCT01939223BayerRegorafenib

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

Start: Dec 2013Est. completion: Aug 201625 patients
Phase 3Terminated
NCT01774344BayerRegorafenib

Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

Start: May 2013Est. completion: Jul 2019573 patients
Phase 3Completed
NCT01661270SanofiOxaliplatin

A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy

Start: Jul 2012Est. completion: Jul 2015332 patients
Phase 3Completed
NCT01571284SanofiOxaliplatin

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Start: May 2012Est. completion: Jan 2017781 patients
Phase 3Completed
NCT01584830BayerRegorafenib

Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Start: Apr 2012Est. completion: Jan 2016204 patients
Phase 3Completed
NCT01515748SanofiOxaliplatin

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Start: Dec 2011Est. completion: Dec 2021530 patients
Phase 3Completed
NCT01245582SanofiOxaliplatin

Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients

Start: Jul 2011Est. completion: Aug 20150
Phase 3Withdrawn
NCT01327521AccurayCyberKnife

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Start: Feb 20110
Phase 3Withdrawn
NCT01271712BayerRegorafenib

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

Start: Jan 2011Est. completion: Apr 2019199 patients
Phase 3Completed
NCT01108705Bristol Myers SquibbBrivanib

Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment

Start: May 2010Est. completion: Oct 201387 patients
Phase 3Terminated
NCT01103323BayerRegorafenib

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Start: Apr 2010Est. completion: Jan 2014760 patients
Phase 3Completed
NCT01087658SanofiOxaliplatin

Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity

Start: Feb 2010Est. completion: Mar 2013200 patients
Phase 3Completed
NCT00630045SanofiOxaliplatin

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Start: Jan 2008Est. completion: Jun 2015392 patients
Phase 3Unknown
NCT00603577SanofiOxaliplatin

Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

Start: Jan 2008Est. completion: Nov 2009102 patients
Phase 3Terminated
NCT00561470SanofiOxaliplatin

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Start: Nov 2007Est. completion: Jun 20121,226 patients
Phase 3Completed
NCT00471965SanofiOxaliplatin

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

Start: Mar 2007Est. completion: Mar 2010371 patients
Phase 3Completed
NCT00335595SanofiOxaliplatin

Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

Start: Jul 2006Est. completion: Jun 2012480 patients
Phase 3Completed
NCT00305188SanofiOxaliplatin

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Start: Dec 2005Est. completion: Oct 2009879 patients
Phase 3Completed
NCT00208546SanofiOxaliplatin

Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Start: Jun 2005Est. completion: Dec 2009750 patients
Phase 3Completed
NCT00087802SanofiOxaliplatin

Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)

Start: Mar 2004383 patients
Phase 3Completed
NCT00272051SanofiOxaliplatin

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Start: Jul 2002Est. completion: May 2004620 patients
Phase 3Completed
NCT00126256SanofiOxaliplatin

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Start: Feb 2002Est. completion: Feb 2006570 patients
Phase 3Completed
NCT00008281SanofiOxaliplatin

Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Start: Oct 2000
Phase 3Unknown
NCT00386984NovartisSomatostatin

Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma

Start: Oct 1999Est. completion: Feb 2003108 patients
Phase 3Completed
NCT03970447BayerRegorafenib

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Start: Jul 2019Est. completion: Jun 20301,280 patients
Phase 2/3Recruiting
NCT00227617SanofiOxaliplatin

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Start: Jun 2005Est. completion: Feb 201636 patients
Phase 2/3Terminated
NCT00238849SanofiOxaliplatin

Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

40 patients
Phase 2Unknown
NCT07071961BayerRegorafenib

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Start: Feb 2026Est. completion: May 202916 patients
Phase 2Suspended
NCT06902246BayerRegorafenib

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Start: Jan 2026Est. completion: Jan 203130 patients
Phase 2Recruiting
NCT07223567BayerRegorafenib

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Start: Oct 2025Est. completion: Jan 20260
Phase 2Withdrawn
NCT06006923BayerRegorafenib

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Start: Jun 2024Est. completion: Nov 20251 patients
Phase 2Terminated
NCT06087263BayerRegorafenib

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Start: Jun 2024Est. completion: Jul 20343 patients
Phase 2Active Not Recruiting
NCT06246643BayerRegorafenib

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Start: Jan 2024Est. completion: Apr 202813 patients
Phase 2Active Not Recruiting
NCT05900648BayerRegorafenib

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

Start: May 2023Est. completion: Feb 20240
Phase 2Withdrawn
NCT05582031BayerRegorafenib

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Start: Apr 2023Est. completion: Apr 20250
Phase 2Withdrawn
NCT05366829BioGene TherapeuticsTislelizumab

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Start: Jul 2022Est. completion: Jun 2027
Phase 2Recruiting
NCT05134532BayerRegorafenib

Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

Start: Dec 2021Est. completion: Oct 202440 patients
Phase 2Unknown
NCT04757363BayerRegorafenib

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Start: Feb 2021Est. completion: Feb 202739 patients
Phase 2Active Not Recruiting
NCT04704154BayerRegorafenib

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Start: Feb 2021Est. completion: Mar 2024175 patients
Phase 2Completed
NCT04126733BayerRegorafenib

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Start: Oct 2019Est. completion: Mar 202270 patients
Phase 2Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 13,589 patients
Small Molecule is the dominant modality (78% of programs)
17 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)